

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Alonso Garcia Maria Angeles	Nothing to be declared (2016-2017)
Alpert Joseph	<p>Nothing to be declared (2017)</p> <p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Acute coronary syndromes (2016) - Johnson & Johnson : Data Safety Committee for a clinical trial on diabetes therapy (2016) - Novo-Nordisk : Data Safety Committee for a clinical trial on diabetes therapy (2016) - Genzyme/Sanofi Aventis : Data Safety Committee for a clinical trial on diabetes therapy (2016) <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - UptoDate online information in internal medicine : Prognosis for patients with myocardial infarction (2016)
Antman Elliott	<p>1- Financial Declaration</p> <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - TIMI group : multiple research grants to this ARO ---managed through our Department of Medicine at our Hospital (2016-2017)
Apple Fred	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Instrumentation Laboratory : Advisory Board (2016) - HyTest : Board of Directors, Cardiac Biomarker Antibodies (2016) - Philips Healthcare Incubator : Consultant, Cardiac Biomarker Company (2016) - Metanomics : Consultant, Cardiac Biomarker Company (2016) - HyTest Ltd : Board of Directors, Reagent Company (2017)

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Apple Fred	<ul style="list-style-type: none"> - Instrumentation Laboratory : Scientific Advisory Board (2017) - Abbott Laboratories : Speaker Honorarium (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Siemens Healthcare : Non-salaried PI for contracted research studies to Minneapolis Medical Research Foundation of Hennepin County Medical Center (2017) - Beckman Coulter : Non-salaried PI for contracted research studies to Minneapolis Medical Research Foundation of Hennepin County Medical Center (2017) - Abbott Laboratories : Non-salaried PI for contracted research studies to Minneapolis Medical Research Foundation of Hennepin County Medical Center (2017) - Roche Diagnostics : Non-salaried PI for contracted research studies to Minneapolis Medical Research Foundation of Hennepin County Medical Center (2017) <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - Alere : Non-salaried PI for contracted research studies to Minneapolis Medical Research Foundation of Hennepin County Medical Center (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Siemens Healthcare : Research grant non-salaried, cardiac biomarkers (2016) - Beckman Coulter : Research grant non-salaried, cardiac biomarkers (2016) - OrthoClinical Diagnostics : Research grant non-salaried, cardiac biomarkers (2016) - Singulex : Research grant non-salaried, cardiac biomarkers (2016) - Abbott Laboratories : Research grant non-salaried, cardiac biomarkers (2016) - Alere : Research grant non-salaried, cardiac biomarkers (2016) - Roche Diagnostics : Research grant non-salaried, cardiac biomarkers (2016) - Qorvo : Non-salaried PI for contracted research studies to Minneapolis Medical Research Foundation of Hennepin County Medical Center (2017)

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Apple Fred	<p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Associate Editor, Clinical Chemistry; compensated. (2016)</p>
Atar Dan	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Cardiome : antiarrhythmic drugs (2016) - Novartis : Acute Heart Failure (2016-2017) - Boehringer-Ingelheim : Anticoagulants (2016-2017) - BMS/Pfizer : anticoagulants (2016-2017) - Bayer Healthcare : anticoagulants (2016-2017) - Merck Sharp & Dohme : Antithrombotic therapy (2016-2017) - St Jude Medical : Devices (2016-2017) - Vifor International : Heart failure (2016-2017) - Astra Zeneca : Platelet inhibition (2016-2017) - Sanofi Aventis : antiarrhythmic drugs (2017) - Amgen Inc : Lipid lowering (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - TIMI group : atherosclerosis-modifying agents (2016) - Duke Research Unit : Heart Failure Therapy (2016) - Duke Research Unit : Heart Failure Therapy (Investigator fees) (2017) - Population Research Institute, McMaster, Hamilton, Canada : Stroke prevention in silent AF (investigator fees) (2017)

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Atar Dan	<p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - BMS/Pfizer : Research grant - kryptogenic stroke project (2016) - Medtronic : Research support (device delivery) in kryptogenic stroke trial (2016) - BMS/Pfizer : Research grant - kryptogenic stroke project. (2017) - Medtronic : Research support (device delivery) in kryptogenic stroke trial. (2017)
Bax Jeroen	<p>1- Financial Declaration</p> <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : device therapy (2017) - Medtronic : device therapy (2017) - Biotronik : device therapy (2017) - Edwards Lifesciences : transcatheter heart valves (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Associate Editor JACC, European Associate Editor JNC, Deputy Editor EHJ; (unpaid) steering committees: PROMPT trial(Medtronic) -- TAVR UNLOAD (Edwards) -- EARLY TAVR (Edwards) -- ADMIRE (GE) -- PARSIFAL-pilot (Bayer) -- PANTHEON (Bayer); (unpaid) co-chair TR Global Consensus Committee (2016) - European Associate Editor JNC, Deputy Editor EHJ; (unpaid) steering committees: PROMPT trial(Medtronic) -- TAVR UNLOAD (Edwards) -- EARLY TAVR (Edwards) -- ADMIRE (GE) -- PARSIFAL-pilot (Bayer) -- PANTHEON (Bayer); (unpaid) co-chair TR Global Consensus Committee (2017)
Bonow Robert	<p>Nothing to be declared (2016)</p> <p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - NHLBI : research oversight (2017)

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Bonow Robert	<p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology. - ACC, AHA (2017)</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Editor-in-Chief, JAMA Cardiology (2017)</p>
Bucciarelli-Ducci Chiara	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Circle Cardiovascular Imaging, Inc : Software for cardiac MRI imaging analysis (2016) - Circle Cardiovascular Imaging, Inc : Imaging analysis software (2017)</p> <p>D - Research funding (departmental or institutional) from healthcare industry. - National Institute of Health Research (NIHR) - United Kingdom : Health research (2016)</p>
Canty John	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Lantheus Medical : Nuclear Cardiology Imaging (2017)</p> <p>D - Research funding (departmental or institutional) from healthcare industry. - National Institute for Health Research : Stem cell therapeutics, Sudden Cardiac Death (2017) - Department of Veterans Affairs : Sudden Cardiac Death (2017)</p> <p>E - Research funding (personal). - American Heart Association : Myocardial infarct size (2016) - National Institutes for Health : Stem Cells (2016) - Department of Veterans Affairs : Sudden Cardiac Death; proteomics (2016)</p> <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology. - American Heart Association; American College of Cardiology; European Society of Cardiology (2016)</p>

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Chaitman Bernard	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - NovoNordisk : Clinical Event Committee (2016-2017) - Sanofi Aventis : DSMB (2016-2017) - Relypsa : DSMB (2016-2017) - Gilead : DSMB and Clinical Event Committee (2016-2017) - Daiichi Sankyo : Clinical Event Committee (2017) - Lilly : Clinical Event COmmittee (2017) - Merck Sharp & Dohme : Clinical event Committee (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - NIH : Clinical event committee; Core ECG laboratory (2016-2017)
Crea Filippo	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Advisory Board (2016-2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Phd Research Founding (2016-2017) - Biotronik : Phd Research Founding (2016-2017) <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - Springer : Coronary microvascular dysfunction (2016-2017)
Cutlip Donald	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : Interventional Cardiology (2016-2017)

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Cutlip Donald	<ul style="list-style-type: none"> - Medtronic : Interventional Cardiology (2016-2017) - Celonova : Interventional Cardiology (2016-2017)
De Caterina Raffaele	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Novartis : aliskiren (2016) - Medscape : anticoagulants (2016) - BMS/Pfizer : apixaban (2016) - Boehringer-Ingelheim : dabigatran (2016) - Lilly : Diabetes (2016) - Elsevier : Editor-in-Chief, Vascular Pharmacology (2016) - Bayer Schering Pharma : rivaroxaban (2016) - Merck Sharp & Dohme : vorapaxar (2016) - Daiichi Sankyo : edoxaban (2016-2017) - Bristol Myers Squibb/Pfizer : apixaban (2017) - Portola Pharmaceuticals : betrixaban, andexanet alfa (2017) - Boehringer Ingelheim : Pradaxa, Idarucizumab (2017) - Bayer AG : rivaroxaban, aspirin (2017) - Novartis : sacubitril/valsartan (2017) - Astra Zeneca : ticagrelor (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb/Pfizer : apixaban (2017)

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
De Caterina Raffaele	<ul style="list-style-type: none"> - Daiichi Sankyo : edoxaban (2017) - Boehringer-Ingelheim : Pradaxa (2017) - Bayer AG : rivaroxaban (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Novartis : aliskiren and canakinumab trials (2016) - Bristol Myers Squibb/Pfizer Alliance : apixaban (2016) - Bayer Schering Pharma : rivaroxaban (2016)
Devereaux Philip J	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Roche Diagnostics : Cardiology (2016) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Cardiovascular (2016-2017) - Covidien : Cardiovascular (2016-2017) - Roche Diagnostics : Cardiovascular (2016-2017) - Stryker : Cardiovascular (2016-2017) - Abbott Diagnostics : Cardiovascular (2016-2017) - Octopharma : Cardiovascular (2016-2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Dr Devereaux is a member of a research group with a policy of not accepting honorariums or other payments from industry for their own personal financial gain. They do accept honorariums/payments from industry to support research endeavours and costs to participate in meetings. Based on study questions Dr Devereaux has originated and grants he has written, he has received grants from Abbott Diagnostics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers-Squibb, Covidien, Octapharma, Philips Healthcare, Roche Diagnostics and Stryker. Dr Devereaux has participated in an advisory board meeting for GlaxoSmithKline and an expert panel meeting with AstraZeneca and Boehringer Ingelheim". (2016)

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Fox Keith	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Coronary disease (2016-2017) - Regeneron : Coronary disease, hyperlipidemia (2016-2017) - Bayer : Thrombosis (2016-2017) - Janssen-Cilag : Thrombosis (2016-2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Coronary disease (2016-2017)
Gibbons Raymond J	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Medtronic Corporation : medical devices (2016-2017) - Astellas Pharmaceutical : pharmacologic stress testing (2016-2017) - Peer View Insitute : physician education (2016-2017) - lantheus medical imaging : radiopharmaceuticals (2016-2017)
Hamm Christian	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - GlaxoSmithKline : drugs (2016) - Siemens Healthcare : MRI (2016) - Astra Zeneca : drugs (2016-2017) - Boehringer-Ingelheim : drugs (2016-2017) - Daiichi Sankyo : drugs (2016-2017) - Novartis : drugs (2016-2017)

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Hamm Christian	<ul style="list-style-type: none"> - Pfizer : drugs (2016-2017) - Sanofi Aventis : drugs (2016-2017) - Lilly : drugs (2016-2017) - Heart.org : drugs (2016-2017) - Bayer Healthcare : drugs (2016-2017) - Medicines Company : drugs (2016-2017) - Merck Sharp & Dohme : drugs (2016-2017) - Abbott Vascular : interventional devices (2016-2017) - BRAHMS GmbH : markers (2016-2017) - Boston Scientific : PCI (2016-2017) - Medtronic : PCI, Valves (2016-2017) - TIMI group : study advisor (2016-2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Deutsche Forschungsgemeinschaft : experimental (2016-2017) - German Research Foundation : experimental studies (2016-2017)
Jaffe Allan	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott Laboratories : biomarkers (2016) - Roche Diagnostics : biomarkers (2016) - Theheart.org : biomarkers (2016) - Outpost Medical : biomarkers (2016) - NuerogenomeX : Biomarkers (2016)

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Jaffe Allan	<ul style="list-style-type: none"> - Novartis : biomarkers (2016-2017) - Siemens Healthcare : biomarkers (2016-2017) - Beckman Coulter : biomarkers (2016-2017) - Alere : biomarkers (2016-2017) - Sphingotec : Biomarkers (2016-2017) - ET Healthcare : biomarkers (2016-2017) - Becton Dickinson : Biomarkers (2016-2017) - Singulex : biomarkers (2017) - Roche Diagnostics : biomarkers in the past (2017) - Abbott Laboratories : biomarkres (2017)
Januzzi James	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Janacare : biomarker assay development (2016-2017) - Critical Diagnostics : biomarkers (2016-2017) - Roche Diagnostics : biomarkers (2016-2017) - Healthreveal : Healthcare consulting (2016-2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Roche Diagnostics : biomarkers (2016-2017) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Siemens Healthcare : biomarkers (2016) - Singulex : biomarker research (2016-2017) - Prevencio : biomarker research (2016-2017)

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Januzzi James	<ul style="list-style-type: none"> - Amgen : heart failure research (2016-2017) - Boehringer-Ingelheim : heart failure research (2016-2017) - Novartis : heart failure research (2016-2017)
Katus Hugo	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Lixiana_NOAK (2016-2017) - Astra Zeneca : Ticagrelor (2016-2017) - Bayer Vital : Xarelto-NOAK (2016-2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : Biobank (2016-2017) - Philips : MRT (2016-2017)
Lindahl Bertil	<p>Nothing to be declared (2017)</p> <p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Philips : Biomarkers (2016) - Roche Diagnostics : Biomarkers (2016) - BioMérieux S.A : biomarkers (2016) - Thermofischer : Biomarkers (2016) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - BioMérieux S.A : biomarkers (2016)

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Luepker Russell V	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Actelion : Platelet inhibitors (2016-2017) - Bayer : Aspirin (2017) <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - University of Texas Austin : Health Education for children (2016-2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - NIH : Aspirin (2016-2017) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - American Heart Association (2016) - American Heart Association American College of Cardiology (2017)
Lyon Alexander	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulation (2016) - Pfizer : Cardiotoxicity of cancer drugs (2016) - Amgen Inc : Cardiotoxicity of cancer drugs (2016) - Ferring International : Cardiotoxicity of cancer drugs (2016) - Novartis : Heart failure (2016) - Servier : Ivabradine, S44121 (2016) - Roche Pharma : Oncology (2016) - Eli Lilly : Oncology drugs (2016-2017) - Bayer : Anticoagulation, rivaroxaban (2017)

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Lyon Alexander	<ul style="list-style-type: none"> - Clinigen Group : Cardio-Oncology, Dexrazoxane (2017) - Roche Pharma : Cardio-Oncology, Herceptin, Perjeta (2017) - Takeda Pharmaceuticals : Cardio-Oncology, Multiple Myeloma, Ixazomib (2017) - Ferring International : Cardiotoxicity of cancer drugs, Degarelix (2017) - Pfizer : Cardiotoxicity of cancer drugs, sunitinib, axitinib, bosutinib (2017) - Boehringer-Ingelheim : Heart failure, diabetes, Empagliflozin (2017) - Novartis : Heart failure, Entresto (2017) - Amgen : Heart failure, myeloma, Omecamtiv, Carfilzomib (2017) - Servier : Ivabradine, S44121, Pixantrone (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Pfizer : Cardiotoxicity of cancer drugs (2016) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Pfizer : Cardiotoxicity (2016) <p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - HEART FAILURE (2017)
Mickley Hans Frederik	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Amgen Inc : Lipid lowering drug (2016-2017) - Merck Sharp & Dohme : Lipid lowering drug (2016-2017)

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Morrow David	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - GlaxoSmithKline : Pharmaceuticals in atherothrombosis (2016) - Abbott Laboratories : Cardiovascular biomarkers (2016-2017) - Roche Diagnostics : Cardiovascular biomarkers (2016-2017) - Astra Zeneca : Pharmaceuticals in atherothrombosis (2016-2017) - Merck Sharp & Dohme : Pharmaceuticals in atherothrombosis (2016-2017) - Aralez Pharmaceuticals : Pharmaceuticals in atherothrombosis (2016-2017) - Peloton : Pharmaceuticals in atherothrombosis (2016-2017) - Verseon : Pharmaceuticals in atherothrombosis (2016-2017) - Bayer AG : Pharmaceuticals in atherothrombosis (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott Laboratories : Cardiovascular biomarkers (2016-2017) - Roche Diagnostics : Cardiovascular biomarkers (2016-2017) - Astra Zeneca : Pharmaceuticals in atherothrombosis (2016-2017) - Daiichi Sankyo : Pharmaceuticals in atherothrombosis (2016-2017) - Novartis : Pharmaceuticals in atherothrombosis (2016-2017) - GlaxoSmithKline : Pharmaceuticals in atherothrombosis (2016-2017) - Amgen Inc : Pharmaceuticals in atherothrombosis (2016-2017) - Merck Sharp & Dohme : Pharmaceuticals in atherothrombosis (2016-2017) - Eisai : Pharmaceuticals in atherothrombosis (2016-2017) - Medicines Company : Pharmaceuticals in atherothrombosis (2017)

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Newby Kristin	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Roche Diagnostics : biomarkers (2016) - Metanomics : biomarkers (2016) - DemeRx : DSMB (2016) - Medscape/theHeart.org : education website (2016) - JACC: BTS : journal Deputy editor (2016) - NIH : MESA OSMB (2016) - BioKier : nutraceutical for diabetes (2016) - Philips Healthcare : POC testing (2016) - Roche Diagnostics : consultation of cardiac biomarkers (2017) - OrthoClinical Diagnostics : consultation on development of hsTnI and bnp assays (2017) - Metanomics : consultation on development of metabolic marker for early heart failure (2017) - Philip Healthcare : consultation on development of point of care biomarker device (2017) - American College of Cardiology : Deputy editor of JACC: BTS (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Verily Life Sciences : research funding for Baseline Study (2016) - Sanofi Aventis : research funding for big data project on medication adherence in diabetes (2016) - GlaxoSmithKline : research funding for biomarker study (2016) - Boehringer-Ingelheim : research funding for COPD study (2016) - NIH : research funding for ECHO coordinating center (2016)

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Newby Kristin	<ul style="list-style-type: none"> - Amylin/BMS : research funding for EXSCEL trial (2016) - GlaxoSmithKline : co-I on study of biomarkers in ACS and post-MI fibrosis (2017) - NIH : co-I research grants in various therapeutic areas; OSMB member; MPI on ECHO coordinating center (2017) - PCORI : electronic health record vs patient self report (2017) - Verily Life Sciences : PI on study of biomarkers; precision medicine (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - PCORI : coI on electronic health record vs patient self report grant (2017) - NIH : research grants in various therapeutic areas; ECHO coordinating center (2017) - GlaxoSmithKline : study of biomarkers in ACS and post-MI fibrosis (2017) - Verily Life Sciences : study of biomarkers; precision medicine (2017) <p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - OTHER - advisory board to nutraceutical company, BioKier. Received stock options instead of direct remuneration (2017) <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Philanthropic Board member: Astrazeneca Healthcare Foundation. No funding to board members. Co-Chair of the Society of Cardiovascular Patient Care Foundation board under ACC. Manage use of legacy funds. No funding to board members. (2016)
O'Gara Patrick	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : TAVR, Exec Cmte Early TAVR Trial (2017) - Medtronic : TMVR, Exec Cmte Apollo Trial (2017) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - NIH : NHLBI CTSN, Co-Chair (2017)

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
O'Gara Patrick	<p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Past President, ACC (2016-2017)
Pinto Fausto Jose	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Novartis : Serelaxin (2016) - Astra Zeneca : Ticagrelor (2016) - Pfizer : Apixaban (2016-2017) - Menarini : Coronary artery disease and hypertension (2016-2017) - Boehringer-Ingelheim : Dabigatran (2016-2017) - Daichi Sankyo : Edoxaban (2016-2017) - Biotronik : Interventional cardiology (2016-2017) - Servier : Ivabradine, Perindopril, Trimetazidine (2016-2017) - Bayer Healthcare : Rivaroxaban (2016-2017) - Vifor International : Patiromer (2017) - Novartis : Serelaxin, Entresto (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulation (2016-2017) - Medtronic : CRT (2016-2017) - Servier : Ivabradine (2016-2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : anti thrombotics (2016-2017)

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Pinto Fausto Jose	<ul style="list-style-type: none"> - Medtronic : CRT (2016-2017) - Servier : Ivabradine (2016-2017) - St Jude Medical : PCI, EP (2016-2017) - GE Healthcare : Ultrasound equipment (2016-2017) - Novartis : Heart Failure (2017)
Robertson Rose Marie	<p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology. <ul style="list-style-type: none"> - American Heart Association American College of Cardiology (2017) </p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. <ul style="list-style-type: none"> - Not sure if these should be included, but wanted to be complete: Unpaid Adjunct Professor of Medicine (Cardiology) Vanderbilt University Medical Center Co-author chapter in 2017 Braunwald Cardiology on Autonomic Cardiovascular Disorders - Publisher Elsevier (in press) Co-PI: NIH-managed, FDA-funded P50 Grant -Tobacco Center on Regulatory Science 2013-2018; ~\$20,000,000 total. No industry support (2016) </p>
Smith Sidney	<p>Nothing to be declared (2016-2017)</p>
Steg Philippe Gabriel	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : antiplatelet agents (2016) - Janssen-Cilag : antithrombotics (2016) - GlaxoSmithKline : antithrombotics (2016) - Medicines Company : antithrombotics (2016) - CSL Behring : lipid lowering drugs (2016) - Servier : antianginal agents (2016-2017) - Bayer : anticoagulants (2016-2017)

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Steg Philippe Gabriel	<ul style="list-style-type: none"> - Astra Zeneca : antiplatelet agents (2016-2017) - Boehringer-Ingelheim : antithrombotics (2016-2017) - Sanofi Aventis : antithrombotics (2016-2017) - Bristol Myers Squibb : antithrombotics (2016-2017) - Lilly : antithrombotics and lipid lowering drugs (2016-2017) - Novartis : consulting (2016-2017) - Pfizer : Events adjudication committee (2016-2017) - Amarin : Lipid compounds (2016-2017) - Novo-Nordisk : Diabetes - consulting (2017) - Amgen Inc : Lipids - consulting (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Clinical trial on lipids (2016-2017) - Servier : Registry on coronary artery disease (2016-2017) - Bayer Healthcare : Antithrombotics- registry analyses (2017)
Thygesen Kristian	<p>Nothing to be declared (2017)</p> <p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott Laboratories : Diagnostics (2016)
Underwood Stephen Richard	<p>Nothing to be declared (2016)</p>

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Underwood Stephen Richard	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - GE Healthcare : Imaging equipment, radiopharmaceuticals, cardiovascular stressor (2017) - Rapiscan Pharma Solutions : Regadenoson (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Spectrum Dynamics Inc : DSPECT solid state gamma camera (2017) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Consis Soc. cons.a.r. : IT support systems (2017)
Van de Werf Frans	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer Ingelheim : tenecteplase ,dabigatran (2016) - Astra Zeneca : ticagrelor (2016) - MSD : vorapaxar,sitagliptin (2016) - Portola Pharmaceuticals : betrixabam (2017) - American Heart Association : senior guest editor circulation (2017) - Boehringer Ingelheim : tenecteplase (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer Ingelheim : tenecteplase (2016)
Virmani Renu	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : Product (2016-2017) - Medtronic : Product (2016-2017) - Bard : Product (2016-2017)

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Virmani Renu	<ul style="list-style-type: none"> - W.L. Gore & associates : Product (2016-2017) - Abbott Vascular : Product (2016-2017) - 480 Biomedical : Product (2016-2017) - Terumo Corporation : Product (2016-2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Lutonix : balloons (2017) - Biosensors : stents (2017) - Boston Scientific : stents and balloons and structural heart (2017) - Abbott Vascular : stents and structural heart (2017) - Edwards Lifesciences : Structural Heart (2017) - Gore : structural heart (2017) - Medtronic : valves and stents (2017)
Vranckx Pascal	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : NOAC (2016) - Bayer Healthcare : NOAC (2016) - Daiichi Sankyo : Edoxaban (2017) - Bayer Healthcare : Rivaroxaban (2017) <p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Supplier (2017)

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Vranckx Pascal	2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology. - Member of the Academic Research Consortium (2017)
Weintraub William	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - SC Pharmaceuticals : Diuretics (2017)</p> <p>D - Research funding (departmental or institutional) from healthcare industry. - Amarin : Omega 3 Fatty Acid (2017)</p> <p>2- Other Positions of Influence</p> <p>2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring. - Christiana Care Health System (2016) - MedStar Washington Hospital Center (2017)</p>
White Harvey	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Pfizer : Cardiology (2016) - Astra Zeneca : Cardiology (2016-2017) - Omthera Pharmaceuticals : Cardiology (2016-2017) - Elsay Inc. : Cardiology (2016-2017) - Luitpold : Cardiology (2017) - Cardiovascular Research Foundation : Cardiology (2017) - American Heart Association : Cardiology (2017) - CSL Behring : Cardiology (2017) - European Society of Cardiology : Cardiology (2017) - The Medicine Company : Cardiology (2017)</p>

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
White Harvey	<ul style="list-style-type: none"> - Sirtex Technology Pty Ltd : Cardiology (2017) - SAHMRI : Cardiology (2017) D - Research funding (departmental or institutional) from healthcare industry. <ul style="list-style-type: none"> - Pfizer : Cardiology (2016) - National Health Institute : Cardiology (2016) - DalGen Products and Services : Cardiology (2016) - Sanofi Aventis : Cardiology (2016-2017) - Omthera Pharmaceuticals : Cardiology (2016-2017) - Eli Lilly and Comapny : Cardiology (2016-2017) - Elsay Inc. : Cardiology (2016-2017) - George Institute : Cardiology (2017) - Intarcia Therapeutics Inc. : Cardiology (2017) - Pfizer New Zealand : Cardiology (2017) - DalCor Pharma UK Inc. : Cardiology (2017)
Zamorano Gomez Jose Luis	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Philips : 3D Echocardiography. (2016) - Servier : Clinical case presentation during ESC Cong 2016 (2016) - Pfizer : speaker CV risk factors. (2016) - MSD : speaker. CV risk factors (2016) - Bayer : afib (2017) - Pfizer : Afib (2017)

Fourth universal definition of myocardial infarction (2018) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	D - Research funding (departmental or institutional) from healthcare industry. - Edwards Lifesciences : Echo for TAVi assessment & Epidemiology of Ao stenosis (2016) - Abbott : Epidemiology study of Mitral regurgitation (2016)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Abaci Adnan	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Daiichi Sankyo : edoxaban (2017) - Servier : Hypertension (2017)
Abid Leila	1- Financial Declaration B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Abbott, novartis sanofi : therapeutic (2017) 2- Other Positions of Influence 2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology. - AMCV (2017)
Aboyans Victor	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Amgen : Hyperlipidemia (2017) - Novartis : Hypertension (2017) - Boehringer-Ingelheim : Oral anticoagulation (2017) - Bayer Healthcare : Oral anticoagulation (2017) - Pfizer/BMS alliance : Oral anticoagulation (2017)
Achenbach Stephan	Nothing to be declared (2017)
Agewall Stefan	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca : Antiplatelet treatment (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Al Hefny Ehab	Nothing to be declared (2017)
Alcalai Ronny	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer : SPEAKER FEES (2017) - Boehringer-Ingelheim : SPEAKER FEES (2017) - Novartis : SPEAKER FEES (2017) - Pfizer : SPEAKER FEES (2017)
Alexander Thomas	Nothing to be declared (2017)
Aliyev Farid	Nothing to be declared (2017)
Antov Slobodan	Nothing to be declared (2017)
Avezum Alvaro	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer : anticoagulation (2017) - Boehringer-Ingelheim : anticoagulation and diabetes (2017)
Baitova Gulmira	Declaration not submitted (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Barbato Emanuele	1- Financial Declaration B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Boston Scientific : Education courses on rotational atherectomy (2017) - Abbott Vascular : Educational courses on FFR (2017) D - Research funding (departmental or institutional) from healthcare industry. - St Jude Medical : Unrestricted grant for an investigator-driven study (2017)
Bassand Jean-Pierre	Nothing to be declared (2017)
Bates Eric R	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Medscape : Educational content (2017)
Beissel Jean	2- Other Positions of Influence 2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology. - Council membre -LRC (Luxembourg Resuscitation Council) -Den-I Syndrome de Marfan.lu Scientific Council -ALAN LU (Maladies rares) -Bletz-Association Luxembourgeoise des concernés d'une lésion cérébrale Asbl (2017)
Bittl John	Nothing to be declared (2017)
Blankenberg Stefan	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer Healthcare : anticoagulation and vascular disease (2017) - Siemens Healthcare : cardiovascular biomarkers (2017) - Singulex : cardiovascular biomarkers (2017) - Abbott Laboratories : cardiovascular biomarkers (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Blankenberg Stefan	<ul style="list-style-type: none"> - Novartis : heart failure and inflammation (2017) - Amgen : lipid therapies (2017) - Astra Zeneca : platelet inhibition (2017)
Breithardt Guenter	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Advisory Board meeting, Bayer Health Care 1000 Euro : Anticoagulants (2017) - Meeting of DSMB, Trial supported by Biotronik 830 Euro : Electrical devices, catheter ablation (2017)
Bueno Hector	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Pfizer : Apixaban (2017) - Bristol Myers Squibb : Apixaban (2017) - Bayer : Aspirin, rivaroxaban (2017) - MEDSCAPE-the heart.org : Inespecific (2017) - Sanofi Aventis : PCSK9 inhibitors (2017) - Novartis : Serelaxin, ACZ885, AHF Academy, (2017) - Astra Zeneca : Ticagrelor (2017) - Ferrer Internacional : Trinomia (polypill) (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Ticagrelor (2017) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - BMS : CV013-011 - STANDUP-AHF trial (2017) - Novartis : LCZ696 - PROMISE trial / PERSPECTIVE trial / PREFER Study (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Bueno Hector	<ul style="list-style-type: none"> - Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2017) - Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2017) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - VP elect. Spanish Society of Cardiology FAHA (2017)
Bugiardini Raffaele	Nothing to be declared (2017)
Chettibi Mohamed	Nothing to be declared (2017)
Claeys Marc	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer : rivaroxabam (2017) - Abbott Vascular/StJude : stents- mitraclip (2017) - Astra Zeneca : ticagrelor (2017)
Coca Antonio	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Merck Serono : Bisoprolol-Amlodipine (2017) - Menarini : Nevibolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2017) - Ferrer Internacional : Torasemide; CardiIncode microchips; Polypill (2017)
Cohen Mauricio	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Medtronic : Coronary stents and transradial catheterization (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Cohen Mauricio	<ul style="list-style-type: none"> - Abiomed : High risk PCI (2017) - Astra Zeneca : Interventional pharmacology (2017) - Merit Medical : Transradial catheterization (2017) - Terumo Medical : Transradial catheterization (2017) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - I am a fellow of the American College of Cardiology, fellow of the Society of Cardiovascular Angiography and Interventions (SCAI), member of the American Heart Association, member of the Sociedad Argentina de Cardiologia, member of the Sociedad Latinoamericana de Cardiologia Intervencionista (SOLACI). (2017)
Colivicchi Furio	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Ezetimibe (2017) - Amgen : PCSK9 inhibitors (2017) - Astra Zeneca : Ticagrelor (2017)
Collet Jean-Philippe	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Lecture fees representing 2000 euros for 2017. (2017) - Roche Diagnostics : Lecture fees representing 800 euros for 2017. (2017) - Bayer Healthcare : Speaker Fees for antiplatelet therapy. This represented 2000 euros in total for 2017. (2017) - Servier : SPEAKER FEES OF 1000 EUROS IN 2017 (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : ACADEMIC RESEARCH DONATION TO THE ACTION FOUNDATION (www.action-fonds.org) (2017) - Bayer AG : ACADEMIC RESEARCH FUNDINGS (ADRIFT TRIALS) to the action study group (www.action-fonds.org) (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<ul style="list-style-type: none"> - Astra Zeneca : ACADEMIC RESEARCH FUNDINGS (ALPHEUS TRIAL) to the action study group (www.action-fonds.org) (2017) - Medtronic : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017) - Bristol Myers Squibb and Pfizer : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)
Coman Ioan Mircea	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : anticoagulants (2017) - Johnson & Johnson : antithrombotic (2017) - Bayer AG : antithrombotic (2017) - Sanofi Aventis : dyslipidemia (2017) - Fournier Laboratories : dyslipidemia (2017) - Amgen Inc : dyslipidemia , (2017) - Novartis : HF (2017) - Vifor International : iron deficiency (2017) - Actelion : PHT (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : anticoagulants (2017) - Johnson & Johnson : antithrombotic (2017) - Bayer AG : antithrombotic (2017) - Sanofi Aventis : dyslipidemia (2017) - Amgen Inc : dyslipidemia (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Coman Ioan Mircea	<ul style="list-style-type: none"> - Fournier Laboratories : dyslipidemia (2017) - Novartis : HF (2017) - Vifor International : iron deficiency (2017) - Actelion : PHT (2017)
Corbett Simon	<p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Member of UK National Institute of Health and Care Excellence (NICE) Standing Committee B and C for Guideline Updates (non-financial) (2017)
Damman Peter	<p>1- Financial Declaration</p> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Astra Zeneca : Registration of Acute Coronary Syndrome (2017)
Dangas George	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulant medications (2017) - Philips : Interventional cardiology (2017) - Abbott Vascular : Interventional cardiology (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : anticoagulant medications (2017) - Abiomed : cardiogenic shock (2017) - Boston Scientific : coronary stents (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer : anticoagulant medications (2017) - Daiichi Sankyo : anticoagulant medications (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Dangas George	- Astra Zeneca : Cardiology (2017)
Davlouros Periklis	1- Financial Declaration B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Menarini : Ranolazine (2017) - Astra Zeneca : Ticagrelor (2017)
De Lemos James A	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Quidel Cardiovascular, Inc : Biomarkers (2017) - Ortho Clinical Diagnostics : BNP (2017) - Novo-Nordisk : Diabetes DMSB (2017) - Abbott Diagstoics : hs-cTnI (2017) - Roche Diagnostics : NT-proBNP and hs-cTnT (2017) - Amgen Inc : Steering Committee PCSK9 inhibitor (2017) D - Research funding (departmental or institutional) from healthcare industry. - Abbott Diagnostics : hs-cTnI (2017)
Delgado Victoria	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Abbott Vascular : Mitraclip (2017) D - Research funding (departmental or institutional) from healthcare industry. - Boston Scientific : pacemakers (2017) - Medtronic : pacemakers (2017) - Biotronik : pacemakers (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Delgado Victoria	- Edwards Lifesciences : valves (2017)
Dingli Philip	Nothing to be declared (2017)
Elezi Shpend	Nothing to be declared (2017)
Filippatos Gerasimos	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Novartis : Heart Failure (2017) - Servier : Heart Failure (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer : CKD (2017) - Vifor International : Heart failure (2017) - Boehringer-Ingelheim : Heart failure, Diabetes (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Medtronic : Devices (2017) - European Union : Heart Failure (2017)
Fitzsimons Donna	Nothing to be declared (2017)
Fry Edward	<p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - American College of Cardiology Political Action Committee (U.S.) (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Gaemperli Oliver	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - GE Healthcare : Imaging (2017)</p>
Gilard Martine	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer Healthcare : medication (2017) - Medtronic : TAVI (2017)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca : medication (2017) - Terumo Inc : OCT/stent (2017) - Abbott Vascular : Stent (2017) - Edwards Lifesciences : TAVI (2017) - GE Healthcare : Technology (2017)</p>
Granger Christopher B	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca : CV Medicine (2017) - Bayer : CV Medicine (2017) - Boehringer-Ingelheim : CV Medicine (2017) - Boston Scientific : CV Medicine (2017) - Daiichi Sankyo : CV Medicine (2017) - Medtronic : CV Medicine (2017)</p>

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Granger Christopher B	<ul style="list-style-type: none"> - Novartis : CV Medicine (2017) - Pfizer : CV Medicine (2017) - GlaxoSmithKline : CV Medicine (2017) - Bristol Myers Squibb : CV Medicine (2017) - Merck Sharp & Dohme : CV Medicine (2017) - NIH : CV Medicine (2017) - AbbVie : CV Medicine (2017) - Janssen : CV Medicine (2017) - Armetheon : CV Medicine (2017) - Verseon : CV Medicine (2017) - Sirtex : CV Medicine (2017) - Gilead Science : CV Medicine (2017) - Rho : CV Medicine (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : CV Medicine (2017) - Bayer : CV Medicine (2017) - Boehringer-Ingelheim : CV Medicine (2017) - Daiichi Sankyo : CV Medicine (2017) - Janssen-Cilag : CV Medicine (2017) - Novartis : CV Medicine (2017) - Pfizer : CV Medicine (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Granger Christopher B	<ul style="list-style-type: none"> - Bristol Myers Squibb : CV Medicine (2017) - Medtronic Foundation : CV Medicine (2017) - Armetheon : CV Medicine (2017) - FDA : CV Medicine (2017) - Glaxo Smith Kline : CV Medicine (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Duke has relationships with most Healthcare companies : Medical (2017) <p>2- Other Positions of Influence</p> <p>2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - Duke Clinical Research Institute (2017)
Grosu Aurel	Nothing to be declared (2017)
Gudnason Thorarinn	Nothing to be declared (2017)
Gustiene Olivija	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet, ticagrelor (2017) - Krka Pharma : Atorvastatin, ezetemibe, bisoprolol (2017) - Berlin Menarini : Hypertension, infarction, Zofenopril (2017) - Servier : Stable angina, hypertension, ivabradin, bisoprolol, perindopril (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Amgen : Amgen, Principal Investigator, Start of End of Study Visit Period: 2-Sept-16, The EOS Visit period will complete on 11-Nov-16 (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Halvorsen Sigrun	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Antithrombotic treatment (2017) - Astra Zeneca : Anti-thrombotic treatment (2017) - Boehringer-Ingelheim : Anti-thrombotic treatment (2017) - Pfizer : Anti-thrombotic treatment (2017) - Bayer AS : Anti-thrombotic treatment (2017) - Sanofi Aventis : Cholesterol lowering treatment (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Novartis : Heart failure (2017)
Hasdai David	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : brilinta (2017) - Pfizer : eliquis (2017) - Boehringer-Ingelheim : pradaxa (2017) - Sanofi Aventis : praluent (2017) - Medicines Company : rephata (2017) - Bayer : xarelto (2017)
Hayrapetyan Hamlet	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Servier : Arterial Hypertension (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Hindricks Gerhard	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott : Pacemaker, Ablation (2017) - Biosense Webster : Pacemaker, Ablation (2017) - Biotronik : Pacemaker, catheter (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott, Biotronik, Medtronic, Boston Scientific : Electrophysiology, arrhythmias (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the Helios Hospital Group. (2017)
Hlatky Mark	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Janssen-Cilag : Diabetes medications (2017) - Blue Cross Blue Shield Association : Health Insurance (2017) - Acumen : Medicare Data Analysis (2017) <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - Up-To-Date : Textbook (2017) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Milestone Pharmaceuticals : Arrhythmia (2017) - St Jude Medical : Coronary disease (2017) - HeartFlow : Imaging (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Ibanez Borja	<p>1- Financial Declaration</p> <p>D - Research funding (departmental or institutional) from healthcare industry. - Astra Zeneca : I am Co-PI of a multicenter scientific grant for a study on behavioral change for primary prevention, NO drugs or products involved. (2017)</p> <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - My center (CNIC) is a non-profit organization that receives royalties for the sales of a polypill (trinomía) which is constituted by aspirin-ramipril-simvastatin. I am not involved in the scientific development and have NO direct interest (no personal benefits). (2017)</p>
Iung Bernard	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Boehringer Ingelheim : Anticoagulants (2017) - Novartis : Heart failure drugs (2017) - Edwards Lifesciences : Heart valve prostheses (2017)</p>
Iversen Kasper Karmark	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bristol Myers Squibb : NOAC (2017)</p>
James Stefan	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer : Anti coagulation (2017) - Boston Scientific : Stents (2017)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - jansen : Anti coagulation (2017) - Medicines Company : Anti thrombotics (2017)</p>

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
James Stefan	<ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet (2017) - Abbott : Stents (2017) - Boston Scientific : stents (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer : Anti coagulation (2017) - Astra Zeneca : Anti thrombotics (2017) - Boston Scientific : Stents (2017)
Jernberg Tomas	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Cardiovascular (2017) - Merck Sharp & Dohme : Cardiovascular (2017) - Aspen : Cardiovascular (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Amgen : Cardiovascular (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Cardiovascular (2017)
Juliebo Vibeke	<p>Nothing to be declared (2017)</p>
Juni Peter	<p>1- Financial Declaration</p> <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Anti-platelet Therapy (2017) - Biotronik : Drug-eluting stents (2017) - Biosensors International Group : Drug-eluting stents (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Juni Peter	<p>- The Medicines Company : Thrombin inhibitors (2017)</p> <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <p>- Peter Jüni has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly and The Medicines Company, and serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical and The Medicines Company. (2017)</p>
Kala Petr	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <p>- Astra Zeneca : adjuvant pharmacology (2017)</p> <p>- Boston Scientific : interventional cardiology (2017)</p> <p>- Terumo Inc : interventional cardiology (2017)</p> <p>- Amgen : research drug (2017)</p> <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <p>- Zoll Medical : interventional cardiology (2017)</p> <p>E - Research funding (personal).</p> <p>- Biosensors : interventional cardiology (2017)</p>
Kastrati Adnan	<p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <p>- I have benefitted licence fees related to own patents on drug-eluting stents. (2017)</p>
Knuuti Juhani	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <p>- Astra Zeneca : Consultancy for a research project for ischemic heart disease (2017)</p> <p>- GE Healthcare : Consultancy for myocardial perfusion imaging agent (2017)</p>

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Lancellotti Patrizio	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Servier : Ischemic Heart Disease (2017)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer : NOAC (2017)</p>
Leclercq Christophe	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Abbott : devices (2017) - Boston Scientific : devices (2017) - Medtronic : devices (2017) - Biotronik : devices (2017) - Livanova : devices (2017)</p> <p>D - Research funding (departmental or institutional) from healthcare industry. - Biotronik : devices (2017)</p>
Legutko Jacek	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - MSD : Ezetymib (2017) - Bracco Pharmaceutical : HD-IVUS, FFR (2017) - Siemens Healthcare : Imaging (2017) - Abbott : Interventional cardiology, electrotherapy (stents, balloons, wires, valves, peacemakers, etc.) (2017) - Terumo Inc : Interventional cardiology, electrotherapy (stents, balloons, wires, valves, peacemakers, etc.) (2017) - Balton : Interventional cardiology, electrotherapy (stents, balloons, wires, valves, peacemakers, etc.) (2017)</p>

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Legutko Jacek	<ul style="list-style-type: none"> - Volcano : IVUS, FFR/iFR (2017) - Astra Zeneca : Ticagrelor (2017)
Mahaffey Kenneth W	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Novartis : Consultancy or other services (2017) - Johnson & Johnson : Consultancy or other services (2017) - Bristol Myers Squibb : Consultancy or other services (2017) - WebMD : Consultancy or other services (2017) - Radiometer : Consultancy or other services (2017) - Ablynx : Consultancy or other services (2017) - Elsevier : Consultancy or other services (2017) - Medscape : Consultancy or other services (2017) - Springer Publishing : Consultancy or other services (2017) - Mitsubishi : Consultancy or other services (2017) - Astrazeneca : Consultancy or other services (2017) - Boehringer Ingelheim : Consultancy or other services (2017) - Theravance : Consultancy or other services (2017) - MyoKardia : Consultancy or other services (2017) - Cardiometabolic Health Congress : Consultancy or other services (2017) - Oculeve : Consultancy or other services (2017) - UCSF : Consultancy or other services (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Mahaffey Kenneth W	<ul style="list-style-type: none"> - Merck : Consultancy or other services (2017) - Glaxo Smith Kline : Consultancy or other services (2017) - Baim Institute : Consultancy or other services (2017) - Medergy : Consultancy or other services (2017) - Portola : Consultancy or other services (2017) - BioPrint Fitness : Dr. Mahaffey has equity in this company. (2017) D - Research funding (departmental or institutional) from healthcare industry. <ul style="list-style-type: none"> - Novartis : Research Grant (2017) - Johnson & Johnson : Research Grant (2017) - Astrazeneca : Research Grant (2017) - Merck : Research Grant (2017) - Amgen : Research Grant (No compensation) (2017) - Medtronic : Research Grant (No compensation) (2017) - Luitpold : Research Grant (No compensation) (2017) - St. Jude : Research Grant (No compensation) (2017) - Afferent : Research Grant (No compensation) (2017) - Ferring : Research Grant (No compensation) (2017) - Apple, Inc : Research Grant (No compensation) (2017) - Cardiva Medical, Inc : Research Grant (No compensation) (2017) - Daiichi : Research Grant (No compensation) (2017) - Google (Verily) : Research Grant (No compensation) (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Mahaffey Kenneth W	<ul style="list-style-type: none"> - Sanofi : Research Grant (No compensation) (2017) - Tenax : Research Grant (No compensation) (2017)
Marandi Toomas	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antithrombotics (2017) - Sanofi Aventis : Diabetes (2017)
McDonagh Theresa	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Vifor International : Ferrinject (2017) - Novartis : Honoraria (2017) - Bayer AG : Honoraria (2017)
Mehta Laxmi	<p>1- Financial Declaration</p> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - American Heart Association : Myocardial Infarction (2017) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - American College of Cardiology and American Heart Association (2017)
Morais Joao	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : ATOZET (2017) - Boehringer-Ingelheim : Dabigatran (2017) - Novartis : Entresto (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Morais Joao	<ul style="list-style-type: none"> - Servier : Ivanradina (2017) - Bial Portela : Lipids (2017) - Menarini : Ranolazina (2017) - Bayer Healthcare : Rivaroxaban (2017) - Astra Zeneca : Ticagrelor (2017)
Mueller Christian Eugen	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Antidiabetics (2017) - Servier : Antihypertensive (2017) - Siemens Healthcare : Diagnostics (2017) - Singulex : Diagnostics (2017) - Roche Diagnostics : Diagnostics (2017) - Sanofi Aventis : Lipid lowering (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Beckman Coulter : Diagnostics (2017) - OrthoClinical Diagnostics : Diagnostics (2017) - Singulex : Diagnostics (2017) - Abbott Laboratories : Diagnostics (2017) - Roche Diagnostics : Diagnostics (2017) - Siemens : Diagnostics (2017) - Sphingotec : Diagnostics (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Nedeljkovic Milan	Nothing to be declared (2017)
Parkhomenko Alexander	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - BHFZ : corvitin (2017) - Sanofi Aventis : enoxaparin (2017) - Servier : preductal (2017) - Bayer Healthcare : rivaroxaban (2017) - Astra Zeneca : ticagrelor (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - European Research Foundation FP7 : European Research Foundation FP7 grant 2014-2017 (2017)
Patrono Carlo	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer : Aspirin, Rivaroxaban (2017) - Amgen : Cardiovascular prevention (2017) - GlaxoSmithKline : NSAIDs (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer Healthcare : Aspirin (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Chair of the Scientific Advisory Board of the International Aspirin Foundation (2017)
Piepoli Massimo Francesco	Nothing to be declared (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Pineiro Daniel Jose	Nothing to be declared (2017)
Ponikowski Piotr	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : anticoagulant, diabetes (2017) - Respicardia : devices (2017) - Novartis : heart failure (2017) - Cardiorentis : heart failure (2017) - Berlin Chemie AG : heart failure (2017) - Bayer Healthcare : heart failure (2017) - Vifor Pharma ltd : heart failure (2017) - CIBIEM : heart failure (2017) - Servier : heart failure, coronary artery disease (2017) - Amgen : heart failure, lipids (2017) - Pfizer : lipids, heart failure (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Respicardia : anticoagulant (2017) - BioControl : devices (2017) - Cardionomic : devices (2017) - Impuls Dynamics : devices (2017) - Novartis : heart failure (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> - Bayer Healthcare : heart failure (2017) - CIBIEM : heart failure (2017) - National Institute of Health : heart failure (2017) - Servier : heart failure, coronary artery disease (2017) - Amgen : heart failure, lipids (2017) - European Union grant : heart failure, prevention (2017)
Porela Pekka	<p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - Bayer (advocacy group) (2017)
Radsel Peter	<p>1- Financial Declaration</p> <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Research agency of Slovenia : Cardiovascular medicine (2017)
Richter Dimitrios	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : aortic stenosis (2017) - Menarini : CAD- hypertension (2017) - Novo-Nordisk : diabetes (2017) - Novartis : hypertension (2017) - Unipharma : hypertension-thrombosis (2017) - Abbott : lipids (2017) - Amgen : lipids (2017) - Sanofi Aventis : Lipids (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Richter Dimitrios	<ul style="list-style-type: none"> - Lilly : Lipids (2017) - Unilever : lipids (2017) - Merck Sharp & Dohme : lipids (2017) - Vianex : lipids (2017) - Galenica : Lipids (2017) - Teva Pharmaceutical Industries : lipids, hypertension (2017) - Bayer Healthcare : Thrombosis (2017)
Roffi Marco	<p>1- Financial Declaration</p> <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : Stents (2017) - Medtronic : Stents (2017) - Biotronik : stents (2017) - Terumo Inc : stents (2017) - Abbott Vascular : stents (2017)
Roithinger Franz Xaver	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulation (2017) - Boehringer-Ingelheim : Anticoagulation (2017) - Daiichi Sankyo : Anticoagulation (2017) - St. Jude Medical : Devices (2017) - Merck Ges m b H : Diabetes (2017) - Astra Zeneca : Platelet inhibition (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Roithinger Franz Xaver	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Anticoagulation (2017) - Biotronik : Device Therapy (2017) - Biosense Webster : Electrophysiology (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : Electrophysiology (2017) - Astra Zeneca : Platelet inhibition (2017)
Rubboli Andrea	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : antiplatelet agents (2017) - Boehringer-Ingelheim : non-vitamin K-antagonist oral anticoagulants (2017) - Daiichi Sankyo : non-vitamin K-antagonist oral anticoagulants (2017) - Pfizer : non-vitamin K-antagonist oral anticoagulants (2017) - Bayer Healthcare : non-vitamin K-antagonist oral anticoagulants (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : non-vitamin K-antagonist oral anticoagulants (2017)
Sharma Samin	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : Cardiovascular (2017) - Abbott Vascular : Cardiovascular (2017) - Cardiovascular Systems, Inc. : Cardiovascular (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Shlyakhto Evgeny	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Krka Pharma : Arterial Hypertension (2017) - Novartis : Arterial Hypertension, Heart Failure (2017) - Merck Sharp & Dohme : Atherosclerosis (2017) - Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2017) - Pfizer : General Cardiology (2017)
Simpson Iain A	<p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Member and Past President of the British Cardiovascular Society Member of the Management Board of the American College of Cardiology National Cardiovascular Data Registries (2017)
Sionis Alessandro	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Singulex : Clarity (2017) - Spanish Society of Cardiology : Lectures (2017) - Boehringer-Ingelheim : Pradaxa (2017) - Sanofi Aventis : Praluent (2017) - Bayer : Xarelto (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Singulex : Clarity (2017)
Smajic Elnur	<p>Nothing to be declared (2017)</p>

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Sujayeva Volha	Nothing to be declared (2017)
Tatu-Chitoiu Gabriel Petrisor	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. <ul style="list-style-type: none"> - Astra Zeneca : Acute coronary syndromes (2017) - Zentiva : Acute coronary syndromes (2017) - Boehringer-Ingelheim : Atrial fibrillation (2017) - Pfizer : Atrial fibrillation (2017) - Servier : Hypertension (2017) - Glenmark : Secondary prevention (2017)
Tendera Michal	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. <ul style="list-style-type: none"> - Bayer : Aspirin, acarbose, rivaroxabane (2017) - Kowa : Lipid-lowering agent (2017) - Perfuse Study Group : Lipid-lowweering agent (2017) - Janssen-Cilag : Rivaroxabane (2017) - Servier : Trmetazidine (2017)
Valgimigli Marco	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet agents (2017) - Terumo Inc : Coronary stent (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Valgimigli Marco	<ul style="list-style-type: none"> - Abbott Vascular : Coronary Stent (2017) - Sinomed : Coronary stent (2017) - Bayer : Oral anticoagulation (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Consultancy -TAVI studies (2017) - Biosensors : Speaker Fees (2017) - Astra Zeneca : Ticagrelor (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Anti platelet agents (2017) - Medicure : Antiplatelet agents (2017) - Terumo Inc : Coronary stent (2017) - The Medicines Company : parenteral anticoagulation (2017)
Van Der Wal Allard C	Nothing to be declared (2017)
Windecker Stephan	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer AG : General Cardiology (2017) - Abbott : Invasive Cardiology (2017) - Boston Scientific : Invasive Cardiology (2017) - Edwards Lifesciences : invasive Cardiology (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott : General Cardiology (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> - Boston Scientific : General Cardiology (2017) - St. Jude Medical : General Cardiology (2017) - Amgen Inc. : General Cardiology (2017) - Symetis SA : Invasive Cardiology (2017) - Biotronik : Invasive Cardiology (2017) - Terumo Inc : Invasive Cardiology (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Deputy Editor JACC CV Interventions Section Editor Uptodate Board Member SITEM (Swiss Institute of Translational and Entrepreneur Medicine) Advisor ECRI (European Cardiovascular Research Institute) Course Director, PCR (2017)
Yakovlev Alexey	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Acute coronary syndrome (2017) - Boehringer-Ingelheim : Acute coronary syndrome (2017) - Servier : Acute coronary syndrome (2017) - Sanofi Aventis : Acute coronary syndrome, dyslipidemia (2017)
Zake Ilja	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Krka Pharma : Cardiology (2017) - BGP Products : Cardiology (2017)

Fourth universal definition of myocardial infarction (2018) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Zavatta Marco	1- Financial Declaration B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer Healthcare : Oral anticoagulants (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Amgen : Hyperlipidemia (2016-2017) - Novartis : Hypertension (2016-2017) - Boehringer-Ingelheim : Oral anticoagulation (2016-2017) - Bayer Healthcare : Oral anticoagulation (2016-2017) - Pfizer/BMS alliance : Oral anticoagulation (2016-2017)
Agewall Stefan	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet treatment (2016-2017)
Barbato Emanuele	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : Educational courses on FFR (2016) - Boston Scientific : Education courses on rotational atherectomy (2016-2017) - Abbott Vascular : Educational courses on FFR (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : Unrestricted grant for an investigator-driven study (2016-2017)
Bueno Hector	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott : BVS (2016) - Servier : ivabradine (2016) - Novartis : Serelaxin, ACZ885, AHF Academy (2016)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Bueno Hector	<ul style="list-style-type: none"> - Pfizer : Apixaban (2016-2017) - Bristol Myers Squibb : Apixaban (2016-2017) - Bayer : Aspirin, rivaroxaban (2016-2017) - MEDSCAPE-the heart.org : Inespecific (2016-2017) - Astra Zeneca : Ticagrelor (2016-2017) - Ferrer Internacional : Trinomia (polypill) (2016-2017) - Sanofi Aventis : PCSK9 inhibitors (2017) - Novartis : Serelaxin, ACZ885, AHF Academy, (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Ticagrelor (2016-2017) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Novartis : LCZ696 - PROMISE / PERSPECTIVE (2016) - BMS : CV013-011 - STANDUP-AHF trial (2016-2017) - Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2016-2017) - Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2016-2017) - Novartis : LCZ696 - PROMISE trial / PERSPECTIVE trial / PREFER Study (2017) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - FAHA (2016) - VP elect. Spanish Society of Cardiology FAHA (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Coca Antonio	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Telmisartan; Telmisartan-Amlodipine; Telmisartan-HCTZ (2016) - Merck Serono : Bisoprolol-Amlodipine (2016-2017) - Menarini : Nevibolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2016-2017) - Ferrer Internacional : Torasemide; CardiIncode microchips; Polypill (2016-2017)
Collet Jean-Philippe	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - BMS : apixaban (2016) - Sanofi Aventis : CLOPIDOGREL (2016) - Medtronic : corevalve (2016) - Eli Lilly : PRASUGREL (2016) - Astra-Zeneca : ticagrelor (2016) - MSD : VORAPAXAR (2016) - Bayer Healthcare : xarelto (2016) - Bristol Myers Squibb : Lecture fees representing 2000 euros for 2017. (2017) - Roche Diagnostics : Lecture fees representing 800 euros for 2017. (2017) - Bayer Healthcare : Speaker Fees for antiplatelet therapy. This represented 2000 euros in total for 2017. (2017) - Servier : SPEAKER FEES OF 1000 EUROS IN 2017 (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : APIXABAN (2016) - Medtronic : COREVALVE (2016)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<ul style="list-style-type: none"> - Stago : LABORATORY TEST (2016) - Eli Lilly : PRASUGREL (2016) - FEDERATION FRANCAISE DE CARDIOLOGIE : THROMBOSIS (2016) - ICAN : THROMBOSIS (2016) - Astra Zeneca : TICAGRELOR (2016) - Boston Scientific : ACADEMIC RESEARCH DONATION TO THE ACTION FOUNDATION (www.action-fonds.org) (2017) - Bayer AG : ACADEMIC RESEARCH FUNDINGS (ADRIFT TRIALS) to the action study group (www.action-fonds.org) (2017) - Astra Zeneca : ACADEMIC RESEARCH FUNDINGS (ALPHEUS TRIAL) to the action study group (www.action-fonds.org) (2017) - Medtronic : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017) - Bristol Myers Squibb and Pfizer : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)
Coman Ioan Mircea	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : anticoagulants (2016-2017) - Johnson & Johnson : antithrombotic (2016-2017) - Bayer AG : antithrombotic (2016-2017) - Sanofi Aventis : dyslipidemia (2016-2017) - Fournier Laboratories : dyslipidemia (2016-2017) - Amgen Inc : dyslipidemia , (2016-2017) - Novartis : HF (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Coman Ioan Mircea	<ul style="list-style-type: none"> - Vifor International : iron deficiency (2016-2017) - Actelion : PHT (2016-2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : anticoagulants (2016-2017) - Johnson & Johnson : antithrombotic (2016-2017) - Bayer AG : antithrombotic (2016-2017) - Sanofi Aventis : dyslipidemia (2016-2017) - Amgen Inc : dyslipidemia (2016-2017) - Fournier Laboratories : dyslipidemia (2016-2017) - Novartis : HF (2016-2017) - Vifor International : iron deficiency (2016-2017) - Actelion : PHT (2016-2017)
Delgado Victoria	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott Vascular : Mitraclip (2016-2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : Pacemaker-Heart failure (2016) - Medtronic : Pacemaker-Heart failure (2016) - Biotronik : Pacemaker-Heart Failure (2016) - Edwards Lifesciences : Valvular heart disease (2016) - Boston Scientific : pacemakers (2017) - Medtronic : pacemakers (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Delgado Victoria	<ul style="list-style-type: none"> - Biotronik : pacemakers (2017) - Edwards Lifesciences : valves (2017)
Fitzsimons Donna	Nothing to be declared (2016-2017)
Gaemperli Oliver	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - GE-Healthcare : Imaging (2016) - Amgen Inc : PCSK9 (2016) - Servier : Procorolan (2016) - GE Healthcare : Imaging (2017)
Hindricks Gerhard	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : CIEDs and interventional electrophysiology (2016) - St Jude Medical : CIEDs and interventional electrophysiology (2016) - Biotronik : CIEDs and interventional electrophysiology (2016) - Abbott : Pacemaker, Ablation (2017) - Biosense Webster : Pacemaker, Ablation (2017) - Biotronik : Pacemaker, catheter (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : CIEDs and interventional electrophysiology (2016) - St Jude Medical : CIEDs and interventional electrophysiology (2016) - Abbott, Biotronik, Medtronic, Boston Scientific : Electropysiology, arrhythmias (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Hindricks Gerhard	<p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the Helios Hospital Group. (2017)
lung Bernard	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Heart Valve Prostheses (2016-2017) - Boehringer Ingelheim : Anticoagulants (2017) - Novartis : Heart failure drugs (2017)
Juni Peter	<p>Nothing to be declared (2016)</p> <p>1- Financial Declaration</p> <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Anti-platelet Therapy (2017) - Biotronik : Drug-eluting stents (2017) - Biosensors International Group : Drug-eluting stents (2017) - The Medicines Company : Thrombin inhibitors (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Peter Jüni has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly and The Medicines Company, and serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical and The Medicines Company. (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Katus Hugo	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Lixiana_NOAK (2016-2017) - Astra Zeneca : Ticagrelor (2016-2017) - Bayer Vital : Xarelto-NOAK (2016-2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : Biobank (2016-2017) - Philips : MRT (2016-2017)
Knuuti Juhani	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Consultancy for a research project for ischemic heart disease (2017) - GE Healthcare : Consultancy for myocardial perfusion imaging agent (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Orion : Brain diseases (2016) - AC Immune : Brain diseases (2016) - Antaros : Endocrinology (2016) - Boehringer-Ingelheim : Neurology (2016) - MSD : Neurology (2016) - GE Gealthcare : Neurology (2016)
Lancellotti Patrizio	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : Echo course (2016)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Lancellotti Patrizio	<ul style="list-style-type: none"> - Servier : Ischemic Heart Disease (2016-2017) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Medtronic : Structural disease (2016) - Bayer : NOAC (2016-2017)
Leclercq Christophe	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Sorin Group : devices (2016) - St Jude Medical : devices (2016) - Bayer Healthcare : DOAC (2016) - Boston Scientific : devices (2016-2017) - Medtronic : devices (2016-2017) - Biotronik : devices (2016-2017) - Abbott : devices (2017) - Llvanova : devices (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Biotronik : devices (2017)
McDonagh Theresa	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Vifor International : Ferrinject (2016-2017) - Novartis : Honoraria (2016-2017) - Bayer AG : Honoraria (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Piepoli Massimo Francesco	<p>Nothing to be declared (2017)</p> <p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Servier : Committee member, Speaker fee (2016) - Novartis : Heart Failure Prevention Initiatives, Advisory Board (2016) - Amgen : Metabolic, Lipid (2016) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Novartis : Heart Failure Prevention Initiatives (2016)
Ponikowski Piotr	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott Vascular : devices (2016) - BioControl : devices (2016) - Pfizer : lipids (2016) - Boehringer-Ingelheim : anticoagulant, diabetes (2016-2017) - Respicardia : devices (2016-2017) - Novartis : heart failure (2016-2017) - Cardiorentis : heart failure (2016-2017) - Berlin Chemie AG : heart failure (2016-2017) - Bayer Healthcare : heart failure (2016-2017) - Vifor Pharma ltd : heart failure (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> - CIBIEM : heart failure (2016-2017) - Servier : heart failure, coronary artery disease (2016-2017) - Amgen : heart failure, lipids (2016-2017) - Pfizer : lipids, heart failure (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - DC Device : devices (2016) - Cardioentis : heart failure (2016) - Respicardia : anticoagulant (2016-2017) - BioControl : devices (2016-2017) - Novartis : heart failure (2016-2017) - Bayer Healthcare : heart failure (2016-2017) - CIBIEM : heart failure (2016-2017) - Servier : heart failure, coronary artery disease (2016-2017) - Amgen : heart failure, lipids (2016-2017) - Cardionomic : devices (2017) - Impuls Dynamics : devices (2017) - National Institute of Health : heart failure (2017) - European Union grant : heart failure, prevention (2017)
Richter Dimitrios	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Angelini : Lipids (2016)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Richter Dimitrios	<ul style="list-style-type: none"> - Swisspharma : lipids-hypertension (2016) - Astra Zeneca : lipids-thrombosis (2016) - Pfizer : lipids-thrombosis (2016) - Winmedica : lipids-thrombosis (2016) - Boehringer-Ingelheim : thrombosis (2016) - Menarini : CAD- hypertension (2016-2017) - Novartis : hypertension (2016-2017) - Abbott : lipids (2016-2017) - Amgen : lipids (2016-2017) - Sanofi Aventis : Lipids (2016-2017) - Lilly : Lipids (2016-2017) - Unilever : lipids (2016-2017) - Merck Sharp & Dohme : lipids (2016-2017) - Vianex : lipids (2016-2017) - Galenica : Lipids (2016-2017) - Teva Pharmaceutical Industries : lipids, hypertension (2016-2017) - Bayer Healthcare : Thrombosis (2016-2017) - Edwards Lifesciences : aortic stenosis (2017) - Novo-Nordisk : diabetes (2017) - Unipharma : hypertension-thrombosis (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Roffi Marco	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Terumo Inc : coronary catheters (2016) - Johnson & Johnson : coronary catheters (2016) - Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2016) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : devices (2016) - Medtronic : devices (2016) - Biotronik : devices (2016) - Terumo Inc : devices (2016) - Abbott Vascular : devices (2016) - Boston Scientific : Stents (2017) - Medtronic : Stents (2017) - Biotronik : stents (2017) - Terumo Inc : stents (2017) - Abbott Vascular : stents (2017)
Shlyakhto Evgeny	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Krka Pharma : Arterial Hypertension (2016-2017) - Novartis : Arterial Hypertension, Heart Failure (2016-2017) - Merck Sharp & Dohme : Atherosclerosis (2016-2017) - Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Shlyakhto Evgeny	- Pfizer : General Cardiology (2016-2017)
Simpson Iain A	2- Other Positions of Influence 2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Member and Past President of the British Cardiovascular Society Member of the Management Board of the American College of Cardiology National Cardiovascular Data Registries (2016-2017)
Sousa Uva Miguel	Nothing to be declared (2017) 1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Boehringer-Ingelheim : Dabigatran (2016) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca : Ticagrelor (2016)
Windecker Stephan	1- Financial Declaration B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer AG : General Cardiology (2017) - Abbott : Invasive Cardiology (2017) - Boston Scientific : Invasive Cardiology (2017) - Edwards Lifesciences : invasive Cardiology (2017) D - Research funding (departmental or institutional) from healthcare industry. - St Jude Medical : General Cardiology (2016) - Terumo Inc : General Cardiology (2016) - Bracco Pharmaceutical : General Cardiology (2016) - Boston Scientific : General Cardiology (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> - Abbott : General Cardiology (2017) - St. Jude Medical : General Cardiology (2017) - Amgen Inc. : General Cardiology (2017) - Symetis SA : Invasive Cardiology (2017) - Biotronik : Invasive Cardiology (2017) - Terumo Inc : Invasive Cardiology (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Deputy Editor JACC CV Interventions Section Editor Uptodate Board Member SITEM (Swiss Institute of Translational and Entrepreneur Medicine) Advisor ECRI (European Cardiovascular Research Institute) Course Director, PCR (2017)
Zamorano Gomez Jose Luis	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Philips : 3D Echocardiography. (2016) - Servier : Clinical case presentation during ESC Cong 2016 (2016) - Pfizer : speaker CV risk factors. (2016) - MSD : speaker. CV risk factors (2016) - Bayer : afib (2017) - Pfizer : Afib (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Echo for TAVi assessment & Epidemiology of Ao stenosis (2016) - Abbott : Epidemiology study of Mitral regurgitation (2016)